Obsidian Therapeutics Announces Leadership Transition and Appoints Paul K. Wotton, Ph.D., as Chief Executive Officer


Obsidian Therapeutics announces strategic collaboration with Celgene to develop novel cell therapies with tunable immunomodulatory factors, opening potential for CAR-T and other cellular medicines in new settings


Obsidian Presents Preclinical Data Demonstrating Precise Regulation of Cytokines and CAR in T cells with Destabilizing Domain Technology using FDA-Approved Drugs


Obsidian Presents Preclinical Data at ASGCT Showing Advancement of its Regulated IL12 and IL15 Programs to Enable Safer and More Effective CAR-T Therapies


Obsidian to Present Data on Regulated Cytokine Programs at the Upcoming American Society of Gene and Cell Therapy (ASGCT) 21st Annual Meeting


Obsidian Therapeutics Presents Preclinical Data from Regulated Cytokine Programs that Enable CAR-T Therapies with Controllable Functions


Obsidian Therapeutics to Present at Upcoming Investor Conferences


Obsidian to Present Data on its Destabilizing Domain Technology and Product Programs at the Upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting


Obsidian Therapeutics to Present Data Demonstrating Regulation of Protein Activity with its Next-Generation CAR-T Platform at Keystone Symposium on Emerging Cellular Therapies


Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products

We would like to collect information during your visit to help us better understand site use. This data is anonymized, and will not be used for marketing purposes. Read More on our Privacy Policy page. You can withdraw permission at any time or update your privacy settings here. Please choose below to continue.

Yes, I agree No, Please do not